Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 951 - 1,000 out of 12,306

Document Document Title
WO/2006/012440A8
The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to pr...  
WO/2011/069294A1
The present invention provides N6-substituted adenosine derivatives, N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising said compounds above, and the uses of these compounds in manu...  
WO/2011/070152A2
The present invention relates to novel antiviral compounds, which are aryl 3-deazauridine analogues at the C3 position, to a method for synthesizing said compounds, as well as to the antiviral uses thereof. The compounds are of the gener...  
WO/2010/121576A3
The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compo...  
WO/2011/069688A1
This invention provides phosphate-modified nucleosides represented by the structural formula ( I ): wherein W is O or S, and wherein B, R1; R3 and R2. are as defined herein. These compounds are useful as substrates for DNA/RNA polymerase...  
WO/2011/039221A3
Compounds of formula I : including any possible stereoisomers thereof, wherein: R1 is hydrogen, -C(=O)R6 or -C(=O)CHR7-NH2; R2 is hydrogen; or C1-C6alkyl or phenyl, either of which is optionally substituted with 1, 2 or 3 substituents ea...  
WO/2011/067588A1
The present invention relates to novel intermediates and to an improved process for the preparation of N- functionalised cytidine derivatives such as capecitabine, galocitabine and sapacitabine. Said intermediates are se from a copound o...  
WO/2011/066412A1
The present invention relates to a method of improving the therapeutic effect of acupuncture in a subject. The method involves administering adenosine, an adenosine mimetric, an adenosine modulator, an adenosine transport inhibitor, enzy...  
WO/2011/064303A1
The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but al...  
WO/2011/061114A1
The invention relates to a method for producing protected trinucleotides using a combination of specific protective groups.  
WO/2011/061115A1
The invention relates to solid phase-bound nucleosides, in which the nucleoside is covalently bound to a solid phase by a 3'-O-disulfide bridge, and to a method for the production and use thereof.  
WO/2011/062503A1
The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 2',2'-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to a parenter...  
WO/2011/003018A3
Disclosed are halogenated 2-deoxy-lactone, 2'-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound...  
WO/2011/054179A1
Crystalline form of cladribine characterized by a powder X-ray diffraction pattern having a peak at about 26.1° ± 0.2° two-theta (2θ) is disclosed. An amorphous form of cladribine is also disclosed herein. Either of these forms of cl...  
WO/2011/054289A1
Compounds represented by general formula (I), pharmaceutically acceptable salts and solvates thereof or solvates of pharmaceutically acceptable salts are disclosed. wherein R1, R2, R3, R4, W and formula (II) are defined as in the applica...  
WO/2011/051733A2
The present invention relates to compounds and their use in competitive protein binding assays, for example for use with glycosyl transferase and/or glycoprocessing proteins. The present application also provides kits and apparatuses for...  
WO/2010/135564A3
Disclosed are compounds of formula (I), a derivative, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer. Also disclosed are methods of preparing compound of formula (I), a derivative, or a tau...  
WO/2011/052436A1
Provided is a novel molecule for an antisense by which the expression of a specific gene can be efficiently regulated. As formulae (I) and (II) show, the novel artificial nucleoside has an amide bond introduced into a bridged structure o...  
WO/2011/048148A2
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/048040A1
An aqueous micellar formulation for localised topical application to an animal for the concurrent control of internal and external parasites in and on the animal, the formulation comprising a water-miscible co-solvent, a fatty alcohol al...  
WO/2008/087558A3
The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3' position. The ...  
WO/2011/043491A1
Disclosed is a novel artificial fluorescent nucleic acid base having a functional group, which consists of two or more heterocyclic molecules being polycondensed together, at the 6-position (the 6-position of purine ring) of a purine bas...  
WO/2011/043385A1
Disclosed is a double-stranded nucleic acid wherein at least one of the nucleic acids has an artificial base capable of forming a self-complementary base pair or an artificial base capable of forming a base pair of a heat stability at th...  
WO/2011/039221A2
Compounds of formula I : including any possible stereoisomers thereof, wherein: R1 is hydrogen, -C(=O)R6 or -C(=O)CHR7-NH2; R2 is hydrogen; or C1-C6alkyl or phenyl, either of which is optionally substituted with 1, 2 or 3 substituents ea...  
WO/2010/134992A3
This invention relates to novel method of synthesis of RNA utilizing N-2-acetyl protected guanine as nucleoside base, nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides a...  
WO/2011/040984A1
A method for producing a β-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabin...  
WO/2010/014134A8
Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alon...  
WO/2011/035250A1
Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I.  
WO/2011/034895A1
Embodiments herein report compositions, methods and uses for cytosine triphosphate analogues. In some embodiments, cytosine triphosphate analogues can be used for generating high density fluorescent nucleic acid sequences for a variety o...  
WO/2011/034072A1
A protecting group represented by general formula (I) which is stable under reaction conditions of the nucleic acid synthesis cycle, has small steric hindrance and can be removed under mild conditions using a fluoride ion as a base. In g...  
WO/2011/032034A2
Embodiments are disclosed herein that involve C5-functionalized nucleic acids, which can be used for detecting a target in a nucleic acid. Particular embodiments disclose methods for making these compounds, wherein the compounds can be f...  
WO/2010/101526A9
Described is a new standalone diguanylate cyclase polypeptide having a GGDEF motif and a mutated I-site that does not bind c-di-GMP. We demonstrate that the production yield of c-di-GMP and analogues was significantly increased by mutati...  
WO/2011/020298A1
A process for the preparation of cladribine of API grade is provided by direct coupling of O-protected 2-deoxy-ribofuranose with silylated 2-chloroadenine followed by deprotection of the resultant protected nucleoside in a separate step ...  
WO/2011/022712A1
This invention relates to the use of antivirals and in particular to derivatives of acyclic nucleosides for the treatment of infectious mononucleosis. The invention also provides the use of antivirals and in particular to derivatives of ...  
WO/2011/019031A1
Disclosed is a nucleic acid which has nucleic acid substrate characteristics equivalent to those of dATP, has a low specificity for luciferase, exerts no undesirable effect on enzymatic reactions such as synthesis of a complementary chai...  
WO/2011/017253A1
The present invention provides methods of treating viral induced tumor or viral infections, including administering a compound described in the invention in a therapeutically effective amount. According to some aspect of the present inve...  
WO/2011/010967A1
A process for making a capecitabine or its derivative comprising (a) reacting a compound of the formula (II): wherein each of R1 and R2 independently represents a hydroxyl protecting group, with an acylating agent of formula (III): X-C(=...  
WO/2010/018438A3
The invention relates to the tetrazole glycosides derivatives, which are inhibitors of Sodium dependent glucose co transporter (SGLT), particularly SGLT2 and method of treating diseases, conditions and/or disorders inhibited by SGLT2 wit...  
WO/2011/005595A2
Disclosed herein are compounds that activate RNaseL, methods of synthesizing compounds that activate RNaseL and the use of compounds that activate RNaseL for treating and/or ameliorating a disease or a condition, such as a viral infectio...  
WO/2010/096201A3
The present invention relates to synthesis, purification and methods to obtain high purity novel 2'-arabino-O-methyl nucleosides and the corresponding phosphoramidites of various arabinonucleoside bases and introduction of such units int...  
WO/2011/003025A1
The invention provides methods for the synthesis of cyclic dinucleotides and thiophosphate analogs thereof as well as a new family of analogs of cyclic diguanosine monophosphate that includes a series of seven phosphorothioate derivative...  
WO/2011/003018A2
Disclosed are halogenated 2-deoxy-lactone, 2'-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound...  
WO/2011/002200A2
The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition havi...  
WO/2010/029574A3
An improved process for preparing gemcitabine or salts thereof, comprising the following steps, dissolved 2-Deoxy-2,2- difluoro-D-ribofuranose-3,5-dibenzoate in an organic solvent and allowed to cool to 0 to 10 degree centigrade temperat...  
WO/2011/002917A1
Provided herein are alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositi...  
WO/2010/150789A1
Disclosed is a novel production method for efficiently and easily synthesizing an NC-type nucleoside at a high yield without requiring a step for converting an unnecessary protecting group. Specifically disclosed are a step for inverting...  
WO/2010/150791A1
Disclosed is a novel process for the production of an adenosine tetraphosphate, by which an adenosine tetraphosphate can be synthesized more easily in an enhanced yield in comparison with conventional processes. In the novel process, the...  
WO/2010/135918A1
The present invention provides a didanosine precursor drug which is used as anti-AIDS agent and characterized in that 5'-hydroxyl of didanosine is esterified by L-amino acid. The didanosine precursor drug has structural formula I, in whi...  
WO/2010/138855A1
Disclosed are compounds of formula (I), a derivative, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer. Also disclosed are methods of preparing compound of formula (I), a derivative, or a tau...  
WO/2010/135569A1
Disclosed herein are nucleoside phosphoramidates of formula 4 and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymeras...  

Matches 951 - 1,000 out of 12,306